Antengene
德琪医药
Executive Summary
Antengene is a dual-headquartered (Shanghai/San Diego) biotech with a clear BIOSECURE status, making it an attractive partner for US deals. The company's bi-continental structure suggests strong Western market orientation and regulatory experience. With Hong Kong listing (6996.HK), it has public market access for funding partnerships, though limited public information suggests conducting thorough due diligence on pipeline assets and management depth.
Structure: As a Hong Kong-listed entity with dual headquarters in Shanghai and San Diego, Antengene likely operates through a traditional offshore holding structure rather than a VIE. The San Diego presence indicates established US operations and regulatory infrastructure, which could facilitate partnership execution and regulatory alignment.
BIOSECURE Risk
Company has clear BIOSECURE status with no BCC designation, plus established US operations in San Diego
Key Exposures:
- •Potential supply chain dependencies in China
- •Shanghai headquarters and R&D operations
Mitigation: Dual-headquarter structure with San Diego operations provides natural BIOSECURE risk mitigation
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent deal activity recorded in available data
Approach: Initiate with pipeline assessment and management presentations given limited public information; leverage San Diego operations for initial discussions
Red Flags
- ⚠Limited public information on pipeline and management
- ⚠No visible recent corporate events or deal activity
- ⚠Unclear therapeutic focus and competitive positioning
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.